INTEGRATED BIOPHARMA INC
INBP · OTCMCIK 1016504fmd_0A43BSSGM3GQQECBRM94VESB5DManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2010 to Jun 30, 2026, 66 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 47 | 44 | 50 | 53 | 64 | 56 | 51 | 50 | 54 | 44 |
| Cost of revenue | 40 | 39 | 44 | 46 | 54 | 50 | 47 | 46 | 49 | 43 |
| Gross profit | 7 | 5 | 6 | 7 | 9 | 7 | 4 | 4 | 6 | 1 |
| Realized investment gains (losses) | – | – | – | 0 | 0 | 0 | (0) | 0 | – | – |
| Selling, general and administrative | 3 | 3 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| Operating income | 3 | 2 | 3 | 3 | 6 | 3 | 0 | 0 | 2 | (3) |
| Interest expense | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (1) | (1) | (1) | (0) | 1 | (0) | (0) | 0 | 0 | 0 |
| Income before taxes | 2 | 1 | 2 | 3 | 7 | 3 | 0 | 0 | 2 | (3) |
| Income tax expense | (0) | 0 | 0 | (1) | (1) | (1) | 0 | 0 | 1 | 0 |
| Net income from continuing operations | 2 | 1 | 2 | 4 | 8 | 4 | (0) | 0 | 1 | (3) |
| Net income | 2 | 1 | 2 | 4 | 8 | 4 | (0) | 0 | 1 | (3) |